Nexell Therapeutics Inc

The Irvine developer of cell therapies for cancer and other diseases reported a loss of $8.3 million, or 53 cents a share, for the second quarter, compared with a loss of nearly $9 million, or 57 cents a share, for the same period last year. Revenue climbed to $4.6 million from $1.6 million.

Nexell Therapeutics Inc. said its shares would be delisted from the Nasdaq National Market on Tuesday for failing to meet continued listing rules on minimum bid and market capitalization. The company said it believes its shares would be eligible for quoting on the over-the-counter Bulletin Board. The Irvine-based biotechnology company said in May that it had received a Nasdaq delisting warning. Shares of Nexell closed at 11 cents, down 6 cents, or 35%.

Nexell Therapeutics Inc. said Wednesday that William A. Albright Jr. has been named president and chief operating officer of the Irvine medical company. Albright replaces L. William McIntosh, who will leave the management team but continue to advise the company as a consultant and a director. Albright had been Nexell's senior vice president and chief financial officer. The company develops cell therapies and diagnostics for cancer, autoimmune, metabolic and genetic diseases.

Nexell Therapeutics Inc. said its board authorized management to begin winding down operations, after a lengthy but unsuccessful effort to raise capital or form a business combination with another company. The Irvine-based biotechnology company said its work force will be cut from 23 employees to three as a first step. Nexell is considering such alternatives as liquidation, reorganization under the federal bankruptcy code or dissolution to effect the wind-down.

Nexell Therapeutics Inc., which develops cell therapies for cancers and other diseases, has elevated president and chief operating officer William A. Albright Jr. to chief executive. Albright, who helped craft the Irvine company's strategy of moving more aggressively to develop cell therapies, replaces Richard L. Dunning, who remains chairman. Albright will retain the president's title, but the position of chief operating officer will be eliminated, the company said.

Irvine-based Nexell Therapeutics Inc. said Monday it received a $535,000 grant from the National Institutes of Health and will begin a two-year tumor-cell study.

Nexell Therapeutics Inc. completed a 1-for-4 reverse stock split Thursday. Shares of the Irvine company closed at $12.88, down $2.38, in Nasdaq trading. Shareholders approved a decrease in the number of common shares to 80 million from 160 million. Nexell, which develops and markets cell therapies for cancer and other diseases, has 18.75 million shares of common stock outstanding.

Nexell Therapeutics Inc., an Irvine biotechnology company involved in cancer research, said it's considering finding a buyer for the company, or other alternatives, and that it will run out of cash by July. Its shares Thursday fell 55 cents to close at 53 cents on Nasdaq. Auditors found there was "substantial doubt" about Nexell's ability to continue its operations, the company said in a statement. Company officials didn't return phone calls seeking comment.

Nexell Therapeutics Inc. shares more than tripled Wednesday after the Irvine drug maker said it will have seven years of exclusive U.S. marketing rights for an experimental drug to treat a rare genetic blood ailment. The stock, which had lost 75% of its value this year through Tuesday, climbed $1.65 to $2.40 on Nasdaq. Nearly 8 million shares changed hands, compared with average daily volume of about 84,500 shares over the last three months.

* NetGuru Inc., a Yorba Linda information technology company, reported that its net loss for the first quarter widened to $1.2 million, or 7 cents a share, from $300,000, or 4 cents a share, a year earlier. Revenue fell 7% to $6.8 million. * Lake Forest collectibles company L.L. Knickerbocker Co. reported second-quarter profit of $180,000, contrasted with a net loss of $671,000, or 1 cent a share, for the comparable period last year. Sales declined 24% to $6.7 million.

Nexell Therapeutics Inc. in Irvine said Tuesday it agreed to sell its cell-processing business to its biggest shareholder, Baxter International, for $4.3 million, plus unspecified royalties on future product sales. Nexell announced the transaction in June, but financial details were not disclosed. Nexell's remaining work force was reduced by 18 employees. The companies expect to complete the transaction by Oct. 1, Nexell said.

Struggling Nexell Therapeutics Inc. said Tuesday it will fire two-thirds of its work force and transfer rights to its cell-processing products to its biggest shareholder, Baxter International Inc. The Irvine developer of cell therapies to treat cancer and other diseases, said Baxter's health-care unit will obtain worldwide sales, marketing and distribution rights for Nexell's flagship Isolex magnetic cell-selection system, cell culture and storage containers and other products.

Struggling Nexell Therapeutics Inc. said Tuesday that it will fire two-thirds of its work force and transfer rights to its cell-processing products to its biggest shareholder, Baxter International Inc. The Irvine developer of cell therapies to treat cancer and other diseases said Baxter's health care unit will obtain worldwide sales and marketing and distribution rights for Nexell's flagship Isolex magnetic cell-selection system, cell culture and storage containers, and other products.

Collectibles company L.L. Knickerbocker Co. Inc. in Lake Forest reported a net loss $1.2 million, or 2 cents a share, for the first quarter, compared with a loss of $1.4 million, or 3 cents a share, a year earlier. Sales declined 25% to $5.4 million . . . Nexell Therapeutics Inc., an Irvine biotechnology company, posted a loss $6.1 million, or 39 cents a share, for the first quarter, compared with a net loss of $7.7 million, or 51 cents a share, for the first quarter of 2000.

A federal district court judge in Delaware awarded AmCell Corp. a partial summary judgment in a patent infringement suit filed by Nexell Therapeutics Inc. in March 2000, over rival cell-separation devices. Judge Rodrick McKelvie told AmCell, a U.S.